Coherus Has $2.2bn Revenue Ambition By 2026 – But Humira Is Key

Yusimry Adalimumab Biosimilar Uptake Is ‘Key Swing’ For Company Projections

 
• By Dean Rudge
  
prices for drugs
Coherus has provided a long-term revenue guide • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products